Halozyme Therapeutics (HALO) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $2.7 million.
- Halozyme Therapeutics' Accumulated Depreciation & Amortization rose 384.62% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 384.62%. This contributed to the annual value of $10.3 million for FY2024, which is 720.72% down from last year.
- Per Halozyme Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $2.7 million for Q3 2025, which was up 384.62% from $2.7 million recorded in Q2 2025.
- In the past 5 years, Halozyme Therapeutics' Accumulated Depreciation & Amortization registered a high of $11.1 million during Q4 2023, and its lowest value of $700000.0 during Q3 2021.
- Over the past 5 years, Halozyme Therapeutics' median Accumulated Depreciation & Amortization value was $2.6 million (recorded in 2023), while the average stood at $3.2 million.
- As far as peak fluctuations go, Halozyme Therapeutics' Accumulated Depreciation & Amortization tumbled by 1800.0% in 2021, and later surged by 22775.0% in 2023.
- Over the past 5 years, Halozyme Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $3.0 million in 2021, then skyrocketed by 116.67% to $6.5 million in 2022, then soared by 70.77% to $11.1 million in 2023, then decreased by 7.21% to $10.3 million in 2024, then crashed by 73.79% to $2.7 million in 2025.
- Its Accumulated Depreciation & Amortization was $2.7 million in Q3 2025, compared to $2.7 million in Q2 2025 and $2.7 million in Q1 2025.